Novartis Presentations at the ESMO Congress 2021
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Breast
Poster
Alpelisib (Abstract # 309P)
Antineoplastic (ANP) Therapies (Tx) After Alpelisib (ALP) or Placebo (PBO) + Fulvestrant (FUL) in Patients (Pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–), PIK3CA-Mutated (Mut) Advanced Breast Cancer (ABC): An Analysis From SOLAR-1
Lead Author:
Fabrice André
Poster
Everolimus (Abstract # 238P)
BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer
Lead Author:
Zhimin Shao
Poster
LAG525 + Spartalizumab (Abstract # 275P)
A phase 2 study of LAG525 in combination with spartalizumab (PDR001), PDR001 and carboplatin (carbo), or carbo, as first- or second-line therapy in patients (pts) with advanced (Adv) triple-negative breast cancer (TNBC)
Lead Author:
Lisa A. Carey
Proffered Paper
Ribociclib (Abstract #LBA17)
Overall survival (OS) results from the Phase III MONALEESA (ML)-2 trial of postmenopausal patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib(RIB)
Lead Author:
Gabriel N. Hortobagyi
Poster
Ribociclib (Abstract # 232P)
Longitudinal ctDNA analysis for disease monitoring using a targeted NGS panel in phase I study of ribociclib + ET in Asian patients with HR+/HER2- ABC
Lead Author:
Yoon Sim Yap
Poster
Ribociclib (Abstract # 233P)
Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials
Lead Author:
Peter A. Fasching
Poster
Ribociclib (Abstract # 247P)
Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive locally advanced or metastatic breast cancer (BC): Secondary and exploratory results of phase 3b RIBECCA study
Lead Author:
Thomas Decker
Poster
Ribociclib (Abstract # 292P)
Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
Lead Author:
Luca Malorni
Poster
Ribociclib (Abstract # 324P)
Cardiovascular (CV) Disease and Health Care Utilization (HCU) in patients with Estrogen Receptor Positive (ER+) , HER2 negative (HER2-) Advanced Breast Cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A Retrospective Cohort Study
Lead Author:
Susan Dent
Oral
Canakinumab (Abstract # 1194MO)
Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 Phase III results
Lead Author:
Luis Paz-Ares
Poster
Canakinumab (Abstract # 1343P)
Understanding patient and caregiver perceptions of quality of life (QoL) impacts in lung cancer through social listening
Lead Author:
Michele Montrone
Poster
Canakinumab (Abstract # 1345P)
Using social listening to understand stakeholder perceptions of the patient journey in lung cancer
Lead Author:
Ana C. Rodrigues
Poster
Capmatinib (Abstract # 101P)
The landscape of MET alterations in European cancer patients
Lead Author:
Jürgen Wolf
Poster
Capmatinib (Abstract # 1256P)
Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial
Lead Author:
Rebecca S. Heist
Poster
Capmatinib (Abstract # 1259P)
Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
Lead Author:
Xiuning Le
Poster
Capmatinib (Abstract # 1362TiP)
Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: the GeoMETry-III phase 3 study
Lead Author:
Pierre-Jean Souquet
Poster
Trametinib (Abstract # 1260P)
Clinical outcomes of patients with BRAFV600-mutated metastatic NSCLC (mNSCLC) receiving first-line (1L) dabrafenib–trametinib vs other standard of care in real-world practice
Lead Author:
Barbara Melosky
Poster
Dabrafenib (Abstract # 1088P)
Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: a retrospective observational study (GEM 1901 - DESCRIBE-AD)
Lead Author:
Jose Luis Manzano
Poster
Spartalizumab (Abstract # 1084P)
PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Lead Author:
Caroline Robert
Poster
Trametinib (Abstract # 1075P)
Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma
Lead Author:
Caroline Robert
Poster
177Lu-DOTATATE (Abstract # 1102P)
The phase 3 NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: further survival analyses
Lead Author:
Philippe B. Ruszniewski
Poster
177Lu-DOTATATE (Abstract # 1122TiP)
A phase II trial to evaluate the safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), pheochromocytomas and paragangliomas (PPGLs)
Lead Author:
Mark N. Gaze
Oral
177Lu-PSMA-617 (Abstract # 576MO)
Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Lead Author:
Karim Fizazi
Poster
177Lu-PSMA-617 (Abstract # 647TiP)
PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer
Lead Author:
Scott T. Tagawa
Poster
177Lu-PSMA-617 (Abstract # 648TiP)
PSMAfore: a phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC
Lead Author:
Michael J. Morris